Our findings highlight the possibility of repurposing temozolomide, a drug commonly used to treat brain tumors, for ACC therapy when MGMT is absent in tumor samples while the cancer cells maintain proficient mismatch repair to kill them (Fig. 8; ref. 64). This evidence concerns the gene MGMT and neoplasm.